Secondly, due to limitations in access to clinical genetic testing, we did not systematically evaluate patients for the presence of ENaC or CA12 variants, both of which are potential causes of elevated sweat chlorides and CF-like disease in patients without disease-causing CFTR variants. This evidence concerns the gene CFTR and cystic fibrosis.